Podocalyxin-like protein (PODXL), a transmembrane glycoprotein with anti-adhesive properties, is associated with an aggressive tumor phenotype and poor prognosis of several cancers. To elucidate the biological significance of PODXL and its molecular mechanism in gastric cancer (GC), we investigated the expression of PODXL in GC samples and assessed its effects on biological behaviors and the related signaling pathways in vitro and in vivo. Moreover, the possible and closely interacted partners of PODXL were identified. Our data showed that the protein or mRNA level of PODXL was significantly upregulated in tissues or serum of GC patients compared with normal-appearing tissues (NAT) or those of healthy volunteers. Overall survival (OS) curves showed that patients with high PODXL levels in tissues or serum had a worse 
| INTRODUC TI ON
Gastric cancer (GC) is the 5th most prevalent malignant tumor and the 3rd leading cause of cancer-related death worldwide. In 2012, there were nearly 1 million new cases and more than 700 000 deaths worldwide. 1, 2 Despite the advanced diagnostic techniques and therapeutic approaches, the prognosis of GC patients is unsatisfactory, mainly because of our poor understanding of its causes and pathogenesis. Numerous molecules contribute to GC through partially characterized or unknown mechanisms. 3 Therefore, it is crucial to search for highly specific markers for predicting prognosis and response to therapy. 3, 4 Podocalyxin-like protein is a cell surface transmembrane glycoprotein that belongs to the CD34 family. 5 PODXL was first defined as a heavily sialylated and sulfated membrane protein, which expressed on the apical surface of glomerular epithelial cells or podocytes in the kidney. 6 Subsequent research detected PODXL expression in hematopoietic stem cells, hemangioblasts, vascular endothelial cells, podocytes and a subset of neural progenitors. [7] [8] [9] PODXL mainly regulated cell morphology and adhesion through interacting with intracellular proteins and extracellular ligands. 10 PODXL disrupted cell junction complex localization and decreased tight junctiondependent transepithelial resistance. 11, 12 Moreover, the association of PODXL with actin-binding proteins such as Na + /H + exchanger regulatory factors and ezrin mediated the anti-adhesive and migratory capabilities of tumor cells, which implicated the significant role of PODXL in tumor progression. 13, 14 Podocalyxin-like protein was expressed in diverse malignancies, and its overexpression was linked to a poor prognosis of cancer patients, including prostate cancer, urothelial bladder cancer, colorectal cancer, glioblastoma, pancreatic cancer and lung adenocarcinoma patients. [15] [16] [17] [18] [19] [20] High PODXL expression was associated with features such as large tumor size, high histological grade and undetectable expression of the estrogen and progesterone receptors. 21 Surprisingly, multivariate analysis revealed that women with tumors that expressed high PODXL experienced longer disease-free survival. This was the only evidence that PODXL served as a biomarker in breast cancer with good prognosis. 21 To the best of our knowledge, there are few reports on the mechanism of PODXL in GC progression, although there are reports of the poor prognostic value of PODXL expression for GC patients. [22] [23] [24] RUN and FYVE domain containing 1 (RUFY1) is a member of the RUFY family, whose members contain an N-terminal RUN domain and a C-terminal FYVE domain. 25, 26 RUFY proteins are localized predominantly to early endosomes and participate in the regulation of diverse cellular processes. 25, [27] [28] [29] [30] For example, RUFY1 acted as a downstream effector of Etk. Tyrosine phosphorylation of RUFY1 by Etk might be important for its endosomal localization. 27 RUFY1 regulated integrin trafficking and was involved in the migration of NIH-3T3 fibroblasts. 28 However, its clinical and biological functions in cancers are unknown.
The aim of the present study was to investigate the expression of PODXL in GC tissues and serum, and to assess its effects on biological behaviors in vitro and in vivo. The possible interacting partners of PODXL were explored, and a RUFY1-dependent mechanism involved was also investigated.
| MATERIAL S AND ME THODS

| Clinical specimens and cell culture
Gastric Cells were cultured in RPMI-1640 medium supplemented with 10%
FBS at 37°C in 5% CO 2 .
| Upregulation of podocalyxin-like protein and downregulation of podocalyxin-like protein (or RUN and FYVE domain containing 1) in gastric cancer cells
The full-length coding sequence of PODXL was amplified using RT-PCR from human GC tissues, and the cDNA was inserted into the pMSCV-GFP vector. The PODXL primers were 5′-GAAGATCTCCA GAGGCGACGACACGATGC-3′ and 5′-CCGCTCGAGCTCTGTGGTG CTGCTGGAGGC-3′. The PODXL-specific shRNA (siRNA13-PODXL, siRNA14-PODXL and siRNA15-PODXL) were introduced into cells 
| Immunohistochemistry
Tissues were fixed in neutral-buffered formalin and embedded in paraffin. Sections (4-μm thick) were cut and placed on silane-coated slides. Tissue sections were incubated in a dry oven at 60°C for 1 hour and then deparaffinized in xylene 3 times for 10 minutes; they were rehydrated using a graded series of ethanol concentrations for 5 minutes. 
| Confocal laser scanning microscopy
Gastric cancer cells that differentially expressed PODXL were cultured in 3.5-cm glass-bottom dishes (. 
| Quantitative RT-PCR
Total RNA were extracted, and equivalent amounts of RNA (2 μg)
were reverse-transcribed using the M-MLV reverse transcriptase with oligo (dT). Triplicates were performed using FastStart Universal SYBR Green Master (Roche Diagnostics GmbH, Mannheim, Germany). were synthesized by Sangon Biotech (Shanghai, China). All samples were processed in replicate, and the mRNA levels were quantified and expressed as 1000 × 2 -∆Ct or 2 -∆∆Ct .
| Western blotting and co-immunoprecipitation analyses
Total proteins were prepared using standard procedures and 
| Silver staining and sample processing
Protein bands in the analytical gels were visualized using the 
| Mass spectrometry and data analysis
Samples were resuspended in 40 μL of aqueous formic acid, and 8 μg of each sample was analyzed using an Ultimate 3000
RSLCnano, coupled with an Orbitrap Elite mass spectrometer (Thermo Fisher, San Jose, CA, USA). Separations were performed using a Zorbax 300SB-C18 column (Agilent Technologies, Santa Clara, CA, USA). The gradient was linear from 0% to 44% of solvent B for 120 minutes, delivered at 50 μL/min. The Elite-Orbitrap MS was operated in data-dependent mode. Each full MS scan (120 000 resolving power) was followed by MS/MS scans, and the 5 most intense multiply charged ions were dynamically selected and fragmented by collision-induced dissociation at a normalized collision energy = 27%. Samples were analyzed individually and simultaneous proteomic analysis was performed. Tandem mass spectra were extracted and charge-state deconvoluted using Proteome Discoverer (Thermo Fisher, version 1.4.1.14).
We used Sequest to compare all MS/MS spectra with entries in the UniProt database. Searches were performed using a parent ion tolerance = 5 ppm and a fragment ion tolerance = .60 Da.
Trypsin was specified as the enzyme, allowing for 2 missed cleavages. Fixed modification of carbamidomethyl (C) and variable modifications of oxidation (M) and deamidation were specified in Sequest.
| Cell proliferation and colony formation assay
Cells were harvested and incubated (3 × 10 3 cells per well) with 100 μL of culture medium in 96-well plates at 37°C in an atmosphere containing 5% CO 2 ; 10 μL of CCK-8 (Dojindo, Japan) was added to each well. After incubation for 2 hours at 37°C, OD 450 absorbencies at different times were measured using a plate reader (ELx800, BioTek Instruments, USA). Cell growth was expressed as the relative absorbance minus the absorbance of the culture medium.
Single-cell suspensions (3 × 10 3 ) were added to 6-well plates containing complete culture medium with .3% agar on the top of .6% agar in the same medium. The plates were incubated at 37°C
in an atmosphere containing 5% CO 2 for 14 days, and the colonies were fixed and stained with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (5 mg/mL). Colonies containing at least 50 cells were scored.
| Flow cytometric analysis and Hoechst33342 staining
Cell apoptotic rates were determined using the Annexin V Apoptosis 
| Scratch healing, migration and invasion assays
To assess wound healing, cells were wounded using a pipette tip and the adherent cells were gently washed with PBS.
Wound closure was observed for 48 hours. The wound healing activity was expressed relative to the width of wound closure at 0 hours. Transwell chambers (8 μm, 24-well insert, Corning
Lowell, MA, USA) were used for the migration assay. Briefly, 600 μL of medium containing 10% FBS was added to the lower chamber, and 5 × 10 3 cells in 200 μL of serum-free medium were added to the upper chamber. Cells were incubated for 48 hours at 37°C, and the non-migrated cells were removed using cotton swabs. Finally, the insert membranes were stained with .1% crystal violet and the migrated cells were counted using an inverted microscope. For the invasion assay, the insert membranes were coated with diluted Matrigel (BD Biosciences, CA, USA), and the other procedures were the same as for the migration assay.
| Tumor growth in nude mice
After 
| Statistical analysis
Statistical analysis was performed using SPSS 19.0 software (SPSS, Chicago, IL, USA). All data were presented as the mean ± SD.
Differences between groups were analyzed using the Pearson χ was performed to analyze the correlations between PODXL and RUFY1 in tissues or serum. Survival curves were calculated using the Kaplan-Meier method, and the differences among groups were analyzed using the log-rank test. The Cox's regression model was used for univariate analysis and multivariate analysis. P-values <.05
were considered statistically significant.
| RE SULTS
| Analysis of podocalyxin-like protein and RUN and FYVE domain containing 1 expression in gastric cancer patients
As shown in Figure 1A , PODXL and RUFY1 were mainly detected in the cytoplasm. We divided the stained tissues into low and high expression groups according to the total score (<6 or ≥6 Figure 1B ,C). The possible associations between PODXL and RUFY1 in GC samples were evaluated using the SPSS software, and a significant positive correlation was found (r = .241, P = .002; Figure 1D ). We also compared the percentage of RUFY1 (or PODXL) positive staining between PODXL (or RUFY1) positive and negative staining patients. Our data implied that RUFY1
(or PODXL) maintained a higher positive percentage in PODXL (or RUFY1) positive patients (P < .05; Figure S1A ,B). This might imply that these 2 molecules are closely correlated in GC tissues.
Overall survival curves were plotted, and the curves showed that GC patients with high PODXL levels had a worse 5-year OS compared to patients with low PODXL levels (P = .009). Similarly, high RUFY1 levels also led to a poor prognosis in GC patients (P = .011; Figure 1E ,F).
The univariate and multivariate analysis using Cox's proportional hazards model showed that high protein expressing levels of tissue PODXL and RUFY1 retained as independent and significant prognostic factors for survival (PODXL, HR = 3.9, 95%CI = 2.272-6.695, P = .0001, Table   S1 ; RUFY1, HR = 1.799, 95%CI = 1.009-3.208, P = .047, Table S2 ). and TNM stage (P < .05; Table 1 ).
3.3 | Podocalyxin-like protein and RUFY1 mRNA were elevated in the serum of gastric cancer patients and associated with prognosis
As shown in Figure 2A , our results from qRT-PCR analysis showed that the levels of PODXL in serum were significantly higher than those of healthy volunteers (normal group; P < .05). Furthermore, PODXL mRNA levels in patients with lymph node metastases (Lx group), advanced stage (III-IV) or distant metastases (M1) were higher than those without lymph node metastases (L0), who were early stage (I-II) or who were without distant metastases (M0) (P < .05; Figure 2B-D) . Similar results were observed in GC patients with high serum RUFY1 levels (P < .05; Figure 2E -H). We also collected the paired postoperative GC blood specimens on the 7th day post-surgery. The data showed that both PODXL and RUFY1 mRNA levels significantly decreased after tumor resections when compared to their corresponding preoperative expressions, respectively (P < .05; Figure S2A ,B).
To verify whether the tissue PODXL (or RUFY1) expression in GC patients was associated with its expression in serum, we first determined the tissue mRNA expressions of these 2 molecules. Our results showed that both PODXL and RUFY1 were significantly overexpressed in tumor tissues compared to the NAT (P < .05; Figure S3A ,B). Interestingly, the tissue mRNA expression of PODXL (or RUFY1) was also closely positively correlated with the corresponding levels in serum (P < .05; Figure S3C ,D). TA
Moreover, PODXL mRNA levels in the serum were closely associated with those of RUFY1 (r = .596, P = .000; Figure 2I ). The survival analysis indicated that the OS of patients with high serum levels of PODXL or RUFY1 was significantly shorter than that of patients with low PODXL or RUFY1 levels (P < .05; Figure 2J ,K).
Similarly, the univariate and multivariate analysis also confirmed that overexpression of serum PODXL or RUFY1 could serve as an independent prognostic factor for GC survival (PODXL, HR=2.87, 95%CI = 1.693-4.865, P = .001, Table S3 ; RUFY1, HR = 3.857, 95%CI = 2.244-6.63, P = .001, Table S4 ). Human PODXL cDNA were inserted into pMSCV-GFP vectors, and transfection efficiencies were determined using qRT-PCR and western blotting (P < .05; Figure 3C -E). The effects of stable PODXL knockdown in SGC-7901 cells were validated using qRT-PCR and western blotting, and confirmed that PODXL expression was significantly downregulated, particularly when cells were transfected with the siRNA designated 13-PODXL (P < .05; Figure 3F -G). CSLM images revealed that PODXL localized in the cytoplasm of SGC-7901 cells, which was consistent with the analysis of GC tissues by IHC ( Figure 3H ).
| Establishment of cell lines that differentially expressed podocalyxin-like protein
| Restoring podocalyxin-like protein expression promoted the proliferation and colony formation and inhibited the apoptosis of gastric cancer cells
Podocalyxin-like protein promoted the growth of SGC-7901 cells at 72 and 96 hours compared with that of Con238 cells. In contrast, downregulation of PODXL was associated with growth inhibition at 72 and 96 hours compared with control-transfected cells (P < .05; Figure 4A ). Apoptosis-related proteins Caspase-3, Bax and Bcl-2, and invasion-promoting proteins MMP2 and MMP-9 were detected using western blotting. PODXL overexpression in SGC-7901 cells increased the levels of Bcl-2, MMP-2 and MMP-9 and decreased the levels of Caspase-3 and Bax, while PODXL knockdown had the opposite effects (P < .05; Figure 4B ,C). Our data also demonstrated
F I G U R E 2 Analysis of the expression of podocalyxin-like protein (PODXL) and RUN and FYVE domain containing 1 (RUFY1) mRNA in gastric cancer (GC) serum and the association of expression levels with the prognosis of GC patients. A, Serum PODXL levels in GC patients were significantly increased compared with those of healthy volunteers (normal group). B-D, Serum PODXL levels in GC patients with positive lymph node metastases (Lx group), advanced stage (III-IV) or distant metastases (M1) were higher than those without lymph node metastases (L0), of early stage (I-II) or without distant metastases (M0). E, Serum RUFY1 levels in GC patients were significantly increased compared with those of healthy volunteers (normal group). F-H, Serum RUFY1 levels in GC patients with positive lymph node metastases (Lx group), advanced stage (III-IV stage) or distant metastases (M1) were higher than those without lymph node metastases (L0), of early stage (I-II stage) or without distant metastases (M0)
. I, PODXL mRNA levels in the serum of GC patients were significantly associated with RUFY1 (r = .596 P = .000). J and K, Survival analysis indicated that GC patients with high levels of serum PODXL or RUFY1 had a shorter OS compared with those with low PODXL or RUFY1 levels (*P < .05) that restoring PODXL expression significantly promoted colony formation of GC cells, whereas inhibition of PODXL expression significantly decreased the number of colonies (P < .05; Figure 4D -E).
Two similar experiments (Annexin-V and Hoechst33342 staining)
showed that PODXL decreased the apoptotic rate of SGC-7901 cells compared with that of the control group, whereas interfering PODXL expression altered the apoptotic rates of GC cells (P < .05; Figure 4F -I). Similar results were also confirmed in another cell line MKN-45 (P < .05; Figure S4A -E). 
| Restoring podocalyxin-like protein promoted the wound healing, migration and invasion of gastric cancer cells and associated with the activation of PI3K/AKT, NF-κB and MAPK/ERK signaling pathways in vitro
| Restoring podocalyxin-like protein promoted tumorigenesis in vivo
We further investigated whether PODXL promoted tumorigen- 
| Podocalyxin-like protein interacted with RUN and FYVE domain containing 1 in gastric cancer cells in vitro
To further explore the mechanism of PODXL, we conducted MS analysis to identify MFF, GRP78, TGM3, RUFY1, FSH6Q2, CALL5, TBA1B and ACTB as proteins that potentially interacted with PODXL ( Figure 7A,B) . In fact, except for the 2 host genes (TBA1B and ACTB), the mRNA expressing changes of another 6 genes after PODXL overexpression, including MFF, GRP78, TGM3, RUFY1, UBC (FSH6Q2) and CALML5 (CALL5), were determined. As shown in Figure S5 , RUFY1 might be one of the molecules most influenced molecules by PODXL (P < .05). Therefore, we chose RUFY1 for further study. We performed co-IP assays to confirm the presence of F I G U R E 5 Restoring podocalyxin-like protein (PODXL) expression promoted the wound healing, migration and invasion of gastric cancer (GC) cells, and activated the PI3K/AKT, NF-κB and MAPK/ERK signaling pathways in vitro. A, Wound healing assay and statistical analysis. C-F, Migration, invasion assay and statistical analysis. G and H, PODXL activated the PI3K/AKT, NF-κB and MAPK/ERK signaling pathways in vitro via upregulation of the levels of phosphorylated PI3K, AKT, MAPK, NF-κB and ERK1, whereas the total levels of PI3K, AKT, MAPK, NF-κB and ERK1 were unchanged (*P < .05) PODXL/RUFY1 complexes in SGC-7901 cells ( Figure 7C ). The data strongly suggested that PODXL closely interacted with RUFY1 in GC cells. However, the upstream or downstream relationships between PODXL and RUFY1 were unknown. Therefore, we performed western blotting to evaluate the levels of PODXL and RUFY1 in GC cells stably overexpressing PODXL that were transfected with a RUFY1-specific siRNA. Figure 7D showed that overexpressed PODXL Compared with the PODXL group, knocking down RUFY1 expression significantly reversed these biological activities and protein expressions induced by PODXL. We previously showed that restoring PODXL increased the phosphorylation levels of PI3K, AKT, MAPK, NF-κB and ERK1. Similar effects were exerted on RUFY1 expression, and the RUFY1 siRNA significantly inhibited the levels of p-PI3K, p-AKT, p-MAPK, p-NF-κB and p-ERK1 without changes in the levels of the cognate unphosphorylated forms, which might partially explain the oncogenic roles of RUFY1 in GC.
When we re-examined the levels of protein expressions between the PODXL and PODXL-siRNA-RUFY1 groups, we found that silencing RUFY1 could downregulate the levels of p-PI3K, p-AKT, p-MAPK, p-NF-κB and p-ERK1 ( Figure 9G ,H). These findings suggested that the PODXL promoted GC progression in vitro through interacting and upregulating RUFY1 expression in GC cells.
| RUN and FYVE domain containing 1 knockdown attenuated podocalyxin-like proteininduced tumorigenesis in vivo
The regulatory effects of PODXL on RUFY1 were also investigated in vivo. Figure 10A ,B shows that enhanced PODXL promoted tumor formation in vivo and silencing RUFY1 inhibited tumor growth.
PODXL simultaneously expressed in siRNA-RUFY1 cells reduced their growth rate from day 14 compared with PODXL-expressing GC cells (P < .05). The tumor weights and Ki67 staining confirmed that RUFY1 knockdown attenuated PODXL-induced tumorigenesis in vivo (P < .05, Figure 10C -E).
We determined the levels of p-AKT and p-NF-kB in mice tissues. Our data showed that knocking down RUFY1 expression significantly downregulated the expression of p-AKT and p-NF-kB compared with the siRNA-Con568 group. Re-expressing PODXL increased the levels of p-AKT and p-NF-kB, while silencing RUFY1 expression in the PODXL-siRNA-RUFY1 group led to attenuated expression of p-AKT and p-NF-kB compared with the PODXL group ( Figure 10E ). These data indicated that RUFY1 might serve as a downstream target of PODXL and a key mediator of PODXL-related signaling pathways in vivo.
| D ISCUSS I ON
Podocalyxin-like protein is a transmembrane glycoprotein with anti-adhesive properties that was first identified in the kidney. 7 In 2003, the role of PODXL in cancer was first described in testicular cancer. 31 Since then, mounting evidence had demonstrated that PODXL is overexpressed in diverse cancers and is associated with a more aggressive tumor phenotype and poor outcomes. 
33-36
A study employing tissue microarrays and 2 antibodies (HPA2110 and HES9) to evaluate PODXL expression in GC tumors from 337 patients demonstrated the prognostic role of PODXL in GC. 22 Similarly, a study of 174 patients with esophageal or gastric adenocarcinoma revealed that PODXL expression was an independent prognostic biomarker for reduced time to recurrence and poor OS. 23 Here, we used the IHC method to detect PODXL expression in GC tissues and F I G U R E 1 0 RUN and FYVE domain containing 1 (RUFY1) knockdown attenuated podocalyxin-like protein (PODXL)-induced tumorigenesis in vivo. A, RUFY1 knockdown significantly inhibited tumorigenesis in nude mice and attenuated the PODXL-induced changes in tumor formation. B, Tumor growth curves were generated each week. C, Tumor weights were compared. D, E, Histological analysis revealed that RUFY1 knockdown significantly decreased the expression of Ki67 and the levels of p-Akt and p-NF-κB expressions, and attenuated the PODXL-induced changes of signaling proteins (*P < .05) their corresponding NAT. A similar analysis performed by others also indicated that PODXL was a target gene of miR-509-3-5p in GC patients and mediated tumor progression. 24 To further explore the molecular mechanisms of PODXL in GC, we conducted MS analysis and identified 8 proteins, including MFF, GRP78, TGM3, RUFY1, FSH6Q2, CALL5, TBA1B and ACTB as the PODXL potential targets. Among these interacted molecules, RUFY1 might be considered as one of the possible interacting partners of PODXL. Therefore, we chose RUFY1 for further study.
Subsequently, we analyzed 130 GC samples and found that RUFY1 levels were higher in GC tissues or serum. RUFY1 protein expression in tissues was significantly associated with the tumor size, depth of cancer invasion, distant metastasis and TNM stage of GC patients.
Elevated serum RUFY1 was significantly associated with positive lymph node metastases, advanced disease stage and distant metastases. Our survival analyses indicated that GC patients with high RUFY1 levels in tissues or serum had a poorer 5-year OS compared with patients with low RUFY1. Similar to the role of PODXL, both tissue and serum RUFY1 proved to be independent prognostic factors for GC survival. These results indicated that RUFY1 promoted disease progression and might serve as a prognostic biomarker of GC.
To further prove our previous speculation that PODXL mediated GC progression via a RUFY1-dependent mechanism, the co-IP and western In conclusion, we presented evidence for a major role of PODXL and RUFY1 as tumor-promoting genes during gastric carcinogenesis.
The levels of PODXL and RUFY1 might serve as novel and potential prognostic biomarkers. More importantly, we confirmed the presence of PODXL/RUFY1 complexes in GC cells. PODXL promoted GC progression via a RUFY1-dependent signaling mechanism. Our results suggested new therapeutic opportunities for GC that focuses on PODXL.
Targeting the PODXL/RUFY1 complex might improve therapy. 
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